Janssen-Cilag International NV today presented the first reported primary treatment outcome data from The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration- resistant prostate cancer (mCRPC), at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark.
Janssen-Cilag International NV today presented the first reported primary treatment outcome data from The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration- resistant prostate cancer (mCRPC), at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark.
The preliminary data suggest that chemotherapy-naïve patients benefit more from treatment than post-chemotherapy patients, and that after first line docetaxel treatment, patients have a higher prostate- specific antigen (PSA) response when treated with androgen receptor-targeted agents than with taxanes.1
“The Prostate Cancer Registry provides unique insights into the treatment of mCRPC patients from a large, real-world population. With enrolment now complete at over 3,000 patients across 16 countries, there is no other registry in advanced prostate cancer of this size that has produced such a large volume of data,” said Dr Simon Chowdhury, Guy’s Hospital, London. “The Prostate Cancer Registry is helping us to address a critical gap in our understanding of the real-world management of patients with mCRPC. This involves studying patients who have high rates of comorbidities and use multiple medications, who are usually excluded from clinical trials. Every patient is different and it is extremely important for clinicians to be able to understand how men with mCRPC respond to medications to ensure that we chose the very best treatment for each individual. I look forward to seeing further data as the Registry continues.”
The preliminary data from The Prostate Cancer Registry presented at ESMO 2016 suggest that chemotherapy-naïve patients had a longer median time to next therapy (601 days for abiraterone acetate and 503 days for enzalutamide) than post- chemotherapy patients (428 days for abiraterone acetate and 366 days for enzalutamide) when treated with androgen receptor-targeted agents. Chemotherapy- naïve patients also had a higher PSA response than post-chemotherapy patients when treated with either androgen receptor-targeted agents or taxanes.
Data from the study also suggest that for patients who have had first line docetaxel treatment, PSA response at Month 3 was higher with androgen receptor-targeted agents (31% with abiraterone acetate and 39% with enzalutamide) than with taxanes (25% with docetaxel and 29% with cabazitaxel).
Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA) said: “Janssen is proud to support The Prostate Cancer Registry and be a part of this huge endeavour which has never been attempted before. Our aim is to help provide the very best treatments for patients and improve their outcomes. It is great to see preliminary data results of treatment outcomes in mCRPC being presented at ESMO 2016. This is just the beginning and we are excited to see even further data from the Registry emerging over the coming years.”
Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe each year.2 Latest prostate cancer figures show that there are currently three million men living with the disease in Europe.3
References
1 Chowdhury, S. The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC). Abstract #746P. Available at: www.cslide.ctimeetingtech.com/library/esmo/browse/search/LWu#2z95v0qo. Last accessed October 2016.
2 Ferlay J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013; 49: p1374–1403.
3 European Commission. CORDIS Express: Prevention, diagnosis and treatment of prostate cancer. Available at: www.cordis.europa.eu/news/rcn/122705_en.html. Last accessed October 2016
